French CCAFU guidelines on prostate cancer : hormone-sensitive metastatic prostate cancer-update 2020
Copyright © 2020. Published by Elsevier Masson SAS..
OBJECTIVE: The aim of the Cancerology Committee of the French Association of urology (CCAFU) is to propose an update of the guidelines in the management of hormone-sensitive metastatic prostate cancer.
METHODS: A systematic review (Medline) of the literature from 2018 to 2020 was conducted by the CCAFU Findings. Several patterns can be defined at this stage depending on prognostic, metastatic volume, and whether metastases are synchronous or metachronous. Androgenic deprivation therapy (ADT) remains the mainstay of treatment at the metastatic stage. Docetaxel in combination with ADT improves overall survival in synchronous metastatic prostate cancer. In this situation, the combination of ADT with abiraterone is also a standard of care regardless of tumor volume. Recent data have led to the recommendation that ADT should be used in conjunction with a new generation hormone therapy (Apalutamide or Enzalutamide) in metastatic synchronous or metachronous patients, regardless of tumour volume. Local treatment of prostate cancer with radiotherapy improves survival in synchronous oligometastatic patients. Metastases-directed therapy is being evaluated.
CONCLUSION: This update of the French recommendations should help improve the management of patients with prostate cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 30(2020), 8-9 vom: 28. Juni, Seite 430-438 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020 |
|---|
| Beteiligte Personen: |
Rozet, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Androgen Antagonists |
|---|
| Anmerkungen: |
Date Completed 12.04.2021 Date Revised 12.04.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.04.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310972663 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310972663 | ||
| 003 | DE-627 | ||
| 005 | 20231225141241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.04.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM310972663 | ||
| 035 | |a (NLM)32517891 | ||
| 035 | |a (PII)S1166-7087(20)30139-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Rozet, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a French CCAFU guidelines on prostate cancer |b hormone-sensitive metastatic prostate cancer-update 2020 |
| 246 | 3 | 3 | |a Recommandations françaises du comité de cancérologie de l’AFU pour le cancer de la prostate : cancer de prostate métastatique hormono-sensible–actualisation 2020 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2021 | ||
| 500 | |a Date Revised 12.04.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Masson SAS. | ||
| 520 | |a OBJECTIVE: The aim of the Cancerology Committee of the French Association of urology (CCAFU) is to propose an update of the guidelines in the management of hormone-sensitive metastatic prostate cancer | ||
| 520 | |a METHODS: A systematic review (Medline) of the literature from 2018 to 2020 was conducted by the CCAFU Findings. Several patterns can be defined at this stage depending on prognostic, metastatic volume, and whether metastases are synchronous or metachronous. Androgenic deprivation therapy (ADT) remains the mainstay of treatment at the metastatic stage. Docetaxel in combination with ADT improves overall survival in synchronous metastatic prostate cancer. In this situation, the combination of ADT with abiraterone is also a standard of care regardless of tumor volume. Recent data have led to the recommendation that ADT should be used in conjunction with a new generation hormone therapy (Apalutamide or Enzalutamide) in metastatic synchronous or metachronous patients, regardless of tumour volume. Local treatment of prostate cancer with radiotherapy improves survival in synchronous oligometastatic patients. Metastases-directed therapy is being evaluated | ||
| 520 | |a CONCLUSION: This update of the French recommendations should help improve the management of patients with prostate cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Cancer de la prostate | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Diagnostic | |
| 650 | 4 | |a Guidelines | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a Recommandations | |
| 650 | 4 | |a Traitement | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 700 | 1 | |a Hennequin, C |e verfasserin |4 aut | |
| 700 | 1 | |a Beuzeboc, P |e verfasserin |4 aut | |
| 700 | 1 | |a Mathieu, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mongiat-Artus, P |e verfasserin |4 aut | |
| 700 | 1 | |a Beauval, J-B |e verfasserin |4 aut | |
| 700 | 1 | |a Cormier, L |e verfasserin |4 aut | |
| 700 | 1 | |a Fromont-Hankard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ploussard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Renard-Penna, R |e verfasserin |4 aut | |
| 700 | 1 | |a Brureau, L |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 30(2020), 8-9 vom: 28. Juni, Seite 430-438 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2020 |g number:8-9 |g day:28 |g month:06 |g pages:430-438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.04.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2020 |e 8-9 |b 28 |c 06 |h 430-438 | ||